Transforming cell therapy manufacturing: smart automation & genetic modification for scalable success

Thursday 08:00 PDT / 11:00 EDT / 15:00 GMT / 16:00 CET

Sponsor

Transforming cell therapy manufacturing: smart automation & genetic modification for scalable success

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

In-process monitoring of critical process parameters (CPP) is a universal requirement and often cost-driving feature of cell manufacturing. Solutions for closed, automated CPP monitoring are in high demand, yet the successful integration of analytical capabilities as PATs into the cell production workflow is challenged by the limited versatility of bioreactor platforms.

Non-viral genetic modification processes apply external equipment (e.g. Nucleofector® Systems) that requires manual fluid transfers. Ideally a bioreactor platform should provide reliable, closed and automated transfer of target cells.

In this webinar we present how the Lonza Cocoon® Platform demonstrates compatibility with off-the-shelf 908 Devices MAVEN Process Analytical Technology (PAT) analyzer and electroporation using the Lonza Nucleofector® System, enabling closed and automated in-process CPP monitoring and genetic modifications.

Attend this webinar to learn about:

High fidelity, non-invasive in-process sampling of Cocoon® Platform bioreactor and precision delivery of small, representative samples to external devices in a closed and automated manner.
Proven compatibility to establish at-line connection with off-the-shelf 908 Devices MAVEN process analytical devices (PTA) to functionally integrate CPP monitoring into the Cocoon® Platform bioreactor process.
Precision delivery of cell suspensions formulated in the Cocoon® Platform for genetic modification in at-line integrated electroporation unit (Lonza Nucleofector® System)

Peter Szaraz

Senior Scientist at Lonza

Peter Szaraz received his PhD in Molecular Medicine at the University of Siena in 2010. After his Post-doctoral studies at the Department of Physiology at the University of Toronto he worked on the development and clinical translation of cardiovascular regenerative therapies till 2020. He has been a Senior Scientist at Lonza for the past 5 years, working predominantly on the Cocoon® platform for CAR-T therapies.

Graziella Piras

Senior Director of Strategic Alliances and Marketing at 908 Devices

Graziella has over 20 years of experience in developing applications and solutions for upstream bioprocessing. Before joining 908 Devices, she held various positions in marketing and R&D at Thermo Fisher Scientific, leading projects to support the Cell Culture and Cell Therapy business. Graziella obtained her Ph.D. in Biochemistry & Molecular Biology from the University of Liège in Belgium. She did her postdoc studying the role of epigenetic regulation on cancer and development at the National Cancer Institutes in Maryland.